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Abstract
Background: The preferred regimen for HIV post-exposure prophylaxis (PEP) is based mainly on safety and
tolerability because it is given to immunocompetent people without HIV infection for a limited time (28 days). The
frequency of adverse events (AEs) may be > 60%. Although AEs are generally not severe, they can lead to lack of
adherence and failure to complete the regimen. We evaluated the co-formulation elvitegravir, cobicistat,
emtricitabine, and tenofovir disoproxil fumarate (Stribild®) prescribed as one pill taken once daily for HIV PEP in
terms of tolerability and adherence.
Methods: This was a prospective cohort study conducted in one hospital in Paris (April to December 2015. Each
participant receiving the PEP treatment (FTC-150 mg/TDF-245 mg/elvitegravir-200 mg/cobicistat 150 mg once daily)
at the pharmacy of the hospital were recruited consecutively. A clinical visit was planned at 8 weeks after sexual
exposure. Reminders were sent to participants who missed the appointment. A standardized questionnaire was
administered to evaluate completeness and tolerability at week 8.
Results: Overall, 284 participants (86% men; 80% MSM; median age 30 years) were prescribed Stribild®; 50 stopped
after reassessment of risk. Among 234 participants who effectively received PEP, 215 (92%) completed 28 days of
PEP with only three who switched from Stribild® to another PEP because of side effects. More than 60% of
participants reported at least one AE, which were mild to moderate. Fatigue, central neurological and abdominal
side effects were the most frequently reported.
Conclusions: Stribild® seems to be a good option for HIV PEP due to the easiness of use, the side effects profile
and the high completion rate.
Background
The preferred regimen for HIV post-exposure prophylaxis
(PEP) has evolved recently, mainly due to the safety and
tolerability of new antiretroviral drugs. PEP guidelines in
the United States and Europe have been revised to recom-
mend tenofovir disoproxil fumarate (TDF) and emtricita-
bine (FTC) as the preferred backbone drugs, with a
protease inhibitor or an integrase inhibitor as the third
drug [1–3], taking into account the short-term toxicity,
cost, availability and possible risk of transmitted drug
resistance in some contexts.
Antiretroviral drugs have well-documented toxicities
and adverse events (AEs) in patients living with HIV/
AIDS, but the occurrence of AEs during PEP might
differ because the drugs are given to immunocompetent
people without HIV infection for a limited time (28 days).
The incidence of AEs related to PEP regimens may be >
60% with 3-drug regimens [4]. Although these AEs are
generally not severe, experience suggests that they can
lead to lack of adherence, and a substantial proportion
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of people for whom PEP is recommended fail to
complete their prescribed regimen [5]. A simple and
well-tolerated regimen may improve the acceptability
and adherence of PEP.
In well-resourced settings, a recent policy shift for HIV
PEP has been toward combining TDF and FTC with ralte-
gravir as the third drug even if data are still limited in this
indication [6]. The short-term tolerability of a regimen
including an integrase inhibitor as a third agent has been
reported in some studies of raltegravir [4, 7, 8]. The main
side effects reported with this combination, are diarrhea
(up to 55%), nausea (27%), headache (15%), fatigue (14%)
and arthralgies and myalgies (8%). However, raltegravir is
currently recommended to be prescribed twice daily,
which may affect adherence. The association of TDF/FTC
with elvitegravir and cobicistat, prescribed as one pill once
daily could be more interesting for HIV PEP but is less
well studied.
The current study evaluated this novel combined HIV
PEP regimen in terms of tolerability and adherence.
Methods
Participants and setting
This prospective study included HIV-negative men and
women ≥ 18 years old who were seen within 48 h after a po-
tential sexual exposure to HIV-1; the sexual exposure could
include anal, vaginal or oral sex, from an HIV-1-infected
partner or high-risk partner of unknown HIV status [1].
Participants were consecutively recruited from St.
Antoine Hospital in Paris between April 1, 2015 and
December 31, 2015, in the emergency department dur-
ing weekends, public holidays and evenings and in the
infectious diseases department during the remaining
time. PEP was systematically initiated when people pre-
sented in the emergency department and indications
were re-assessed during a visit at Infectious Diseases de-
partment 5 days later at most. Thereafter, follow-up
visits were scheduled for all participants in our HIV am-
bulatory care unit.
The study protocol was approved by the institutional re-
view boards of St Antoine Hospital and the Pierre et
Marie Curie University. All participants gave their consent
to have their data recorded and analyzed anonymously.
Study protocol
Trained physicians gave participants who were eligible
for PEP treatment a standardized counseling message
about potential signs and symptoms of AEs and acute
HIV infection. Participants were given a printed card
that indicated how to reach healthcare staff if necessary.
Each participant received the PEP treatment (FTC-
150 mg/TDF-245 mg/elvitegravir-200 mg/cobicistat
150 mg once daily) at the pharmacy of the hospital,
where the 28-day treatment was delivered 3 times, on
days 1, 8 and 15, and where the standardized question-
naire was administered by study staff to evaluate follow-
up and tolerability of treatment during the month. Ad-
vice about medication uptake and side effects were also
provided by pharmacists. A clinical visit was scheduled
at week 8 after exposure, and blood testing was pre-
scribed to examine biological variables, and hepatitis and
HIV serology testing was prescribed on day 15 and week
8. In addition, participants who received the study drug
were given a diary for recording AEs. Participants re-
ceived a reminder call in case of a missed week-8 ap-
pointment (maximum 3 calls). Data about tolerability
were self-reported by participants and were recorded
during the pharmacy or clinical visit or by phone call.
Adherence was determined by self-reporting the com-
pletion of the prophylaxis schedule. Data on AEs were
graded according to the Division of AIDS Table for
Grading the Severity of Adult and Paediatric Adverse
Events and were classified as mild, moderate, severe and
potentially life threatening (Version 1.0).
Data analysis
Demographic, clinical, and behavioral data were collected
in the Diamm® (Micro 6, France) Database. If participants
presented many times for sexual exposure risk, only the
first episode was retained for analysis. All participants
who received Stribild® were included in the main analysis
that take into account participants who were lost to
follow-up with AE assumed (missing = failure). Results are
presented as frequency and 95% confidence intervals (%).
Fisher’s exact test was used to identify significant differ-
ences between categorical variables, and the Wilcoxon-
Mann-Whitney test was used for continuous variables.
Stata v14 was used to analyze data. P < 0.05 was consid-
ered statistically significant.
Results
Between April 1 and December 2015, a total of 364 po-
tentially exposed participants were prescribed PEP
(Fig. 1). Overall, 284 (78%) exposed participants received
Stribild® for 28 days; 50 participants stopped the PEP
earlier because the sexual exposure was considered not
at high risk. PEP was stopped earlier in people who had
sex with people at low risk of transmission or with HIV
patients with undetectable viral load since more than
6 months. These 284 participants were mostly men
(86%), 80% of men who have sex with men and the me-
dian age was 30 years [range 18 to 69] without any dif-
ference between the participants who completed full
course and participants who stopped earlier. A total of
48 patients (17%) indicated that they knew that they
were exposed to an HIV-infected partner but this
partner was not the regular partner for 34 cases (71%),
with no data available on last viral load and current
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antiretroviral treatment. In total, 184 (65%) reported un-
protected anal sex, 74 (26%) vaginal unprotected sex, 26
(9%) oral unprotected sex because of not using condoms
or condom breakage; 142 (50%) reported known expos-
ure to ejaculate. A total of 30 participants (11%) had a
past sexual exposure to HIV with PEP. One participant
had a positive hepatitis B antigen at the first visit.
Side effects could occur very early, and among the 50
participants who received < 5 days of PEP before stop-
ping the treatment when the risk with sexual exposure
was reassessed, 15 (30%; 95%CI, 17.9 to 44.6) reported
experiencing at least one minor or moderate AE, mainly
fatigue, nausea, or vomiting.
More than half of the 234 participants who were pre-
scribed PEP for 28 days (n = 148, 63.2%; 95%CI, 56.7 to
69.4) reported at least one AEs. Among these partici-
pants, 3 stopped the drug after 2, 10 and 11 days be-
cause of moderate or severe side effects and were
switched to another PEP treatment, and 16 participants
were lost to follow-up after a median of 12 days. Data
on tolerability were available for 218 (93%) participants:
100 participants provided tolerability information during
the medical visit at week 8, 104 when visiting the phar-
macy, and 14 participants provided information when
contacted by phone call. Specific adverse events reported
by participants are shown on Table 1. Fatigue and cen-
tral neurological and abdominal side effects were the
most frequent. Three participants showed minor liver
cytolysis (<2.5 the upper limit of normal of AST or
ALT). All these side effects were mild or moderate and
tended to be self-limiting, not resulting in drug discon-
tinuation except in 3 participants. These 3 participants
had to switch their treatment because of moderate and
severe side effects: 2 diarrhea and abdominal pain and 1
Fig. 1 Flow chart of participants who consulted after sexual exposure to HIV infection in one Parisian hospital between April and December 2015.
PEP: HIV post-exposure prophylaxis
Table 1 Specific adverse events reported by participants who
received a full course (28 days) or a short course (5 days) of the
co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir
disoproxil fumarate, one pill, once a day, as post-exposure
prophylaxis (PEP) for sexual exposure to HIV infection
28 days PEP 5 days PEP
Total 218 (100.0)a 50 (100.0)
At least one adverse event 132 (60.6 [54.0–67.1]) 15 (30.0 [16.8–43.1])
Fatigue 57 (26.1 [20.3–32.0]) 5 (10.0 [1.4–18.6])
Abdominal disorders
- Nausea 55 (25.2 [19.4–31.0]) 6 (12.0 [2.7–21.3])
- Vomiting 5 (2.3 [0.3–4.3]) 4 (8.0 [0.2–15.8])
- Diarrhea 37 (17.0 [11.9–22.0]) 1 (2.0 [0–6.0])
- Abdominal pain 18 (8.3 [4.6–11.9]) 0
- Dysphagia 1 (0.5 [0–1.4]) 0
- Dysgueusia 1 (0.5 [0–1.4]) 0
Headache 17 (7.8 [4.2–11.4]) 3 (6.0 [0–12.8])
Vertigo 5 (2.3 [0.3–4.3]) 0
Insomnia 3 (1.4 [0–2.9]) 0
Visual trouble 1 (0.5 [0–1.4]) 0
Arthralgia or myalgia 2 (0.9 [0–2.2]) 0
Fever sensation 3 (1.4 [0–2.9]) 0
Rash 2 (0.9 [0–2.2]) 0
Cytolysis 3 (1.4 [0–2.9]) 0
Data are no. (%, 95% CI)
aData on tolerability were missing for 16 participants who were prescribed
28 days of PEP and were lost to follow-up before the end of treatment
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repeated vomiting episodes. AE occurrence did not differ
by gender, age, type of exposure event or partner HIV
status on statistical analysis. Overall, 11 participants
went to their general practitioner for treatment of the
side effects. No case of mortality due to AEs was re-
ported, and all side effects were reversible at the end of
treatment.
Among 215 participants who completed the PEP for
28 days, data on adherence were available for 195 (91%)
and were considered complete or >95% for all. Results of
HIV serology 2 months after the exposure were available
for 131/234 participants (56%), and none had HIV infec-
tion. Among 50 participants who received < 5 days of
the PEP before stopping when the risk had been reas-
sessed, results of HIV serology 6 weeks after the expos-
ure were available for 10 (20%), and none had HIV
infection.
Discussion
In this study of PEP with co-formulated elvitegravir,
cobicistat, FTC and TDF prescribed as one pill once
daily, side effects were reported by more than half of the
participants, but nearly all completed the full 28 days of
treatment with high adherence and only three had to
switch because of side effects. Tolerability of this new
regimen was unexpectedly no better than previously re-
ported with various PEP regimens, but completion rate
was higher. In seven PEP studies published since 2001,
51% of the total 1009 participants reported at least one
AE and about 20% failed to complete the 28-day course
[5, 9–14]. The most common side effects we found were
similar to those reported in studies with raltegravir, with
similar frequency of nausea, vomiting, diarrhea, abdom-
inal discomfort, headache, and fatigue but less myalgias
or arthralgias [6, 7], which were reported only twice in
our study.
The 1% PEP discontinuation due to AEs we found was
lower than the 20% discontinuation due to AEs with other
standard regimens of ZDV + 3TC + LPV/r [5]. The discon-
tinuation rate we observed was similar to that with ralte-
gravir [7]. However, the simplicity of drug intake with only
one pill daily could improve the treatment completion as
compared with raltegravir, for which previous study re-
ported approximately one quarter of patients consistently
missing their second dose of raltegravir [7].
PEP based on the co-formulation of elvitegravir, cobi-
cistat, FTC and TDF could be one option for PEP at
least in some countries. Its availability is limited in
resource-limited settings. In 2014 in France, the price
for a 28 days full course of Stribild® (980 euros) was close
to the price of the previously recommanded association
of Truvada® and Prezista®/Norvir® (1002 euros). Com-
pared to the other single tablet regimen, Stribild® was
slightly more expensive than Eviplera® (rilpivirine/TDF/
FTC, 756 euros). However, this last association was not
recommanded in case of high viral load (up to 100 000
copies per milliliters) which might occur in case of pri-
moinfection and because of the higher risk of primary
viral resistance of this non nucleosidic inhibitor. We
need more head-to-head comparisons of completion
rates and tolerability of PEP regimens, including newer
integrase inhibitor-based regimens (ie, raltegravir vs
dolutegravir vs elvitegravir) [15, 16].
French national guidelines for follow-up sexual expos-
ure includes HIV antibody testing at baseline and
6 weeks or at baseline and 8 and 16 weeks after the ex-
posure for people who did not or did receive PEP [1]. In
our study, only 56% of people who were prescribed a
complete PEP treatment underwent HIV-testing follow-
up at 8 weeks and 20% of those who stopped PEP be-
cause of low risk. These low percentages are consistent
with previous findings in PEP studies [17, 18]. Besides
PEP prescription, good follow-up was previously found
associated with older age and sexual encounter with a
sex worker [19]. The completeness of HIV-testing
follow-up could be increased by reducing the number of
HIV testings with one HIV-serology testing 6 weeks after
PEP completion, as proposed by the Swedish reference
group for antiretroviral therapy [20], and targeting coun-
seling to people receiving PEP.
Even if data on HIV testing follow-up are limited, the
effectiveness of the co-formulation of elvitegravir, cobici-
stat, FTC and TDF as PEP appears to be good in our
study since no HIV seroconversion occurred during the
follow-up.
The main limitation of this study is the non comparative
design of the study since all participants received the co-
formulation of elvitegravir, cobicistat, FTC and TDF. Data
on other comorbidities or concurrent medication which
could have affected tolerability have not been collected.
Another limitation is the low percentage of HIV serology
follow-up which prevent us to obtain exhaustive data on
Stribild® effectiveness as post exposure prophylaxis.
Conclusions
The co-formulation elvitegravir, cobicistat, FTC and TDF
appeared to be a good option for HIV PEP in high-resource
settings, with the need for appropriate and effective manage-
ment of AEs, which remained frequent although mild.
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